Abstract

The present invention relates to an oligonucleotide comprising one of the following sequence: (TTAGGG) SEQ ID No. 1. (TAGGGT) SEQ ID No. 2, (AGGGTT) SEQ ID No. 3, (GGGTTA) SEQ ID No. 4, (GGTTAG) SEQ ID No. 5 or (GTTAGG) SEQ ID No. 6 or a complementary sequence thereof or a fragment or a variant or a mixture thereof for use in the treatment and/or prevention of a disease characterized by alternative lengthening of telomeres or a non-cancer condition associated with telomere dysfunction and relative pharmaceutical compositions and to relative pharmaceutical composition and method.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A therapeutic combination of a compound having antiestrogenic activity and a CDK4/6 inhibitor is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting mimicking diet for a period of 24-190 hours while the patient is being treated with the therapeutic combination, in which the compound having antiestrogenic activity can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor degrader (SERD) or an aromatase inhibitor (AI).

IPC Classes  ?

• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61P 35/00 - Antineoplastic agents
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present invention relates to at least one reduced caloric intake cycle and at least one immunotherapeutic agent for use in the treatment of cancer. Preferably the cancer is characterized by resistance or partial response to the treatment with at least one immunotherapeutic agent.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising compounds of formula (I), to their medical use and to their process of preparation. The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising compounds of formula (I), to their medical use and to their process of preparation.

IPC Classes  ?

• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• C07D 223/28 - Dibenz [b, f] azepinesHydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
• C07D 267/20 - [b, f]-condensed
• C07D 243/38 - [b, e]- or [b, f]-condensed with six-membered rings
• C07D 487/04 - Ortho-condensed systems
• C07D 495/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam

Abstract

The present invention relates to the use of fasting mimicking diet (FMD) to inhibit growth and/or kill cancer stem cells (CSCs) in combination with at least one anticancer agent selected from: an AKT inhibitor, an hexokinase inhibitor, a PI3K inhibitor, a combination of a PI3K inhibitor and a CDK4/6 inhibitor, or a combination of a mTOR inhibitor and a PI3K inhibitor. FMD in combination with the anticancer agent is particularly effective in the treatment of triple negative breast cancer (TNBC) and reduces cancer stem cells (CSCs) escape pathways. The invention further relates to a method to identify starvation escape pathways in cancer cells, which can be targeted by drugs.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin

Abstract

A therapeutic combination of a compound having antiestrogenic activity and a CDK4/6 inhibitor is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting mimicking diet for a period of 24-190 hours while the patient is being treated with the therapeutic combination, in which the compound having antiestrogenic activity can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor degrader (SERD) or an aromatase inhibitor (AI).

IPC Classes  ?

• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to at least one reduced caloric intake cycle and at least one immunotherapeutic agent for use in the treatment of cancer. Preferably the cancer is characterized by resistance or partial response to the treatment with at least one immunotherapeutic agent.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an oligonucleotide comprising one of the following sequence: (TTAGGG) SEQ ID No. 1, (TAGGGT) SEQ ID No. 2, (AGGGTT) SEQ ID No. 3, (GGGTTA) SEQ ID No. 4, (GGTTAG) SEQ ID No. 5 or (GTTAGG) SEQ ID No. 6 or a complementary sequence thereof or a fragment or a variant or a mixture thereof for use in the treatment and/or prevention of a disease characterized by alternative lengthening of telomeres or a non-cancer condition associated with telomere dysfunction and relative pharmaceutical compositions and to relative pharmaceutical composition and method.

IPC Classes  ?

• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising compounds of formula (I), to their medical use and to their process of preparation.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents
• C07D 223/28 - Dibenz [b, f] azepinesHydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
• C07D 243/38 - [b, e]- or [b, f]-condensed with six-membered rings
• C07D 267/20 - [b, f]-condensed
• C07D 487/04 - Ortho-condensed systems
• C07D 495/04 - Ortho-condensed systems
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam

Goods & Services

Pharmaceutical preparations for use in dermatology; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for use in hematology; pharmaceutical preparations for the treatment of the skeletal system; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the central nervous system; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of the circulatory system; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of hormonal and diabetic disorders; pharmaceutical cough preparations; preparations for treating colds; pharmaceutical preparations for the treatment of flu and headache; pharmaceutical preparations for the treatment of stomach disorders; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for treating muscolar and/or rheumatological diseases; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for treating allergies; pharmaceutical agents affecting metabolism; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for use in oncology; diagnostic preparations and reagents for clinic or medical laboratory; hormones for medical purposes; dietetic substances adapted for medical use, in particular, nutritional supplements, vitamin preparations, herbal supplements and preparations, nutritional drink mixes for use as meal replacements for medical use, meal replacement snacks for medical purposes; food and drinks for babies, infant formula and dietetic products for invalids, in particular food for babies, powdered milk for babies, foods for enteral feedings and dietetic foods adapted for medical purposes. Education and instruction; organisation of seminars, arranging of conventions, courses, events, symposium for educational or cultural purposes; publishing services; publishing of scientific and informative publications, also online; dissemination of educational material in the field of scientific research; developing international student exchange programs. Scientific and technological services including research and development related thereto; scientific and industrial research and analysis; biological research and analysis; scientific, clinical and medical research; basic and clinical research in the field of genetics, stem cell, immunodeficiency and neurodegenerative diseases, proteomics, bioinformatics, neurobiology and molecular biology and diabetes; research in the field of medicine; consultancy in the field of scientific analysis. Medical services, health care services, medical assistance, physical rehabilitation; hospital services; consultancy in the field of medical diagnosis and analysis; consulting services relating to health care.

Abstract

The present invention relates to at least one modulator of PP2A or at least one modulator of PP2A- like phosphatase or at least one modulator of PP2A and PP2A-like phosphatase or a combination of said modulators for use in the treatment of a disease characterized by an alteration in the DNA damage response. The present invention also relates to a method to identify a subject to be treated with a PP2A modulator comprising detecting in the genome of said patient a mutation in PP2A.

IPC Classes  ?

• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 8/68 - Sphingolipids, e.g. ceramides, cerebrosides, gangliosides

Abstract

The present invention relates to 2 cell-like stem cells and particularly, although not exclusively, the generation of such cells from pluripotent stem cells.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells

Goods & Services

Pharmaceutical preparations for use in dermatology; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for use in hematology; pharmaceutical preparations for the prevention of disorders of the skeletal system; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the treatment of disorders of the central nervous system related to cancer, aging and metabolic diseases; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of disorders of the circulatory system related to aging; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of hormonal disorders and diabetes; pharmaceutical cough preparations; preparations for treating colds; pharmaceutical preparations for the treatment of flu and headache; pharmaceutical preparations for the treatment of stomach disorders; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for treating muscular and/or rheumatological diseases; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for treating allergies; pharmaceutical agents affecting metabolism; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for use in oncology; diagnostic preparations and reagents for medical use in a clinic or medical laboratory; hormones; dietetic substances adapted for medical use, in particular, nutritional supplements, vitamin preparations, herbal supplements and preparations, nutritional drink mixes for use as meal replacements for medical use, meal replacement snacks for medical purposes; food and drinks for babies, infant formula and dietetic products for invalids, in particular food for babies, powdered milk for babies, foods for enteral feedings and dietetic foods adapted for medical purposes Scientific and technological services, namely, scientific research, analysis, testing, diagnosis and screening in the field of oncology and cancer research; research and development in the field of oncology, aging and metabolic diseases; scientific and industrial research and analysis services, namely, scientific research, analysis, testing in the field of medicine; biological research and analysis; scientific, clinical and medical research in the field of radiology, chemotherapy, pharmacotherapy, coronary artery bypass surgery; basic and clinical research in the field of genetics, stem cell, immunodeficiency and neurodegenerative diseases, proteomics, bioinformatics, neurobiology and molecular biology and diabetes; scientific research in the field of medicine; consultancy in the field of scientific analysis; none of the foregoing to include educational testing Medical services, health care services in the field of oncology, aging and metabolic diseases, medical assistance, physical rehabilitation in the field of oncology; hospital services; consulting services in the field of medical care, namely, consultancy in the field of medical diagnosis, medical analysis and RNA or DNA analysis for cancer diagnosis and prognosis; consulting services relating to health care

Abstract

A cell stretching device (1) comprising a cell chamber (2) having an upper portion (10) and a lower portion (20), wherein the lower portion (20) of the chamber (2) comprises fixing means (21) for fixing a deformable cell substrate (S) to the cell chamber (2) and defining a stretching region (22) inside the chamber (2) at the lower portion (20), and the upper portion (10) comprises stretching means (11) movable relative to the chamber (2) and acting on the cell substrate (S) and a support element (19) for holding the stretching means (11) and a driving unit (3) coupled to the upper portion (10) of the cell chamber (2) and engageable to the stretching means (11) for mechanically controlling and regulating the movement of said stretching means (11) relative to the cell chamber (2), wherein the stretching means (11) comprise clip members (12) operating inside the stretching region (22), the clip members (12) being configured to clamp the cell substrate (S) at a clamping contact point and to stretch said cell substrate (S) in response to the movement.

IPC Classes  ?

• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors

Abstract

The present invention relates to small RNAs, inhibitors thereof, inhibitors of enzymes producing thereof, and their use to modulate the response of a cell to a DNA damaging event. The invention concerns also a method to detect the presence or quantify DNA damage.

IPC Classes  ?

• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Goods & Services

Medical education services; medical training and teaching; organisation of conferences and symposia in the field of medical science; publication of medical texts; publishing and issuing scientific papers in relation to medical technology. Biological research, clinical research and medical research; providing scientific information in the field of medical disorders and their treatment. Advisory services relating to medical services.

Abstract

The present invention refers to a method for obtaining a CRISPR-Cas system sgRNA library and to the use of the library to select individual cell knock outs that survive under a selective pressure and/or to identify the genetic basis of one or more biological or medical symptoms exhibited by a subject and/or to knocking out in parallel every gene in the genome.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention relates to the combination of at least one agent and a reduced calorie intake for use in the treatment of a blood cancer. In particular the agent is a CD20 inhibitor Bruton's tyrosine kinase inhibitor, a phosphoinositide 3-kinase inhibitor, a class I and/class II histone deacetylase inhibitor, a non-taxane replication inhibitor or a proteasome inhibitor. The combination is advantageous in that it sensitize cancer cells to said agent while it protects normal cells from toxicity induced by said agent.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 31/18 - Sulfonamides
• A61K 31/33 - Heterocyclic compounds
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/69 - Boron compounds
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention relates to an oligonucleotide comprising one of the following sequence: (TTAGGG) SEQ ID No. 1, (TAGGGT) SEQ ID No. 2, (AGGGTT) SEQ ID No. 3, (GGGTTA) SEQ ID No. 4, (GGTTAG) SEQ ID No. 5 or (GTTAGG) SEQ ID No. 6 or a complementary sequence thereof or a fragment or a variant or a mixture thereof for use in the treatment and/or prevention of a disease characterized by alternative lengthening of telomeres or a non-cancer condition associated with telomere dysfunction and relative pharmaceutical compositions and to relative pharmaceutical composition and method.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

The present invention relates to an oligonucleotide comprising one of the following sequence: (TTAGGG) SEQ ID No. 1, (TAGGGT) SEQ ID No. 2, (AGGGTT) SEQ ID No. 3, (GGGTTA) SEQ ID No. 4, (GGTTAG) SEQ ID No. 5 or (GTTAGG) SEQ ID No. 6 or a complementary sequence thereof or a fragment or a variant or a mixture thereof for use in the treatment and/or prevention of a disease characterized by alternative lengthening of telomeres or a non-cancer condition associated with telomere dysfunction and relative pharmaceutical compositions and to relative pharmaceutical composition and method.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

An inhibitor of Wnt/β-catenin signaling for use in the treatment and/or prevention of a pathology characterized by vascular malformation. The inhibitor may be a small molecule, a protein, a peptide or an antisense nucleic acid. The invention also relates to pharmaceutical compositions and to method of treatment.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/05 - Phenols
• A61K 31/12 - Ketones
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A method is disclosed for the generation of pluripotent cells from non-pluripotent cells.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The invention relates to a biomarker of the plasminogen activation system and/or the interaction between uPAR and VN and its use as a prognostic/diagnostic marker and/or to stratify subject affected by tumours for treatment with inhibitors of the plasminogen activation system and/or the interaction between uPAR and VN. The biomarker is also used to monitor over time the molecular efficacy of inhibitors in blocking components of the plasminogen activation system and/or the interaction between uPAR and VN in patients under therapy.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to small RNAs, inhibitors thereof, inhibitors of enzymes producing thereof, and their use to modulate the response of a cell to a DNA damaging event. The invention concerns also a method to detect the presence or quantify DNA damage.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to variants of the urokinase plasminogen activator receptor (uPAR) that display remarkably increased vitronectin (VN) binding activity, possibly caused by a more efficient exposure of the VN binding site. The present invention also refers to antibodies raised against said uPAR variants, able to bind to the VN binding site of uPAR and then acting as inhibitors of uPAR functions, acting as functional antagonists of VN activated-uPAR functions. In the present invention such antibodies are monoclonal, polyclonal, synthetic or recombinant derivatives thereof, as synthetic antibodies (scFv) from phage-display libraries. Antibodies of the invention act as competitive antagonists.

IPC Classes  ?

• A61K 38/49 - UrokinaseTissue plasminogen activator

Abstract

The invention relates to inhibitors of the urokinase-type plasminogen activator receptor (uPAR). The generated inhibitors are bivalent uPAR-ligands containing the receptor binding domains of the extracellular protease urokinase-type plasminogen activator (uPA) and of the extracellular matrix protein vitronectin (VN), in different configurations, linked by a scaffold. The present invention also refers to the above molecules for use as a medicament, in particular for treatment of cancer, and for diagnostic purposes.

IPC Classes  ?

• A61K 38/49 - UrokinaseTissue plasminogen activator

Abstract

The invention relates to methods of diagnosis and prognosis of cancer, and in particular NSCLC, the methods comprising determining the expression level of one or more genes. In some embodiments the invention relates to prognosis of early stage NSCLC.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention provides materials and methods for classifying tumours, for diagnosing and treating cancers and for determining a prognosis and/or treatment regimen for an individual with cancer. Serine/threonine kinases which show altered gene status and/or expression levels in tumour cells compared to normal cells are identified herein and these serine/threonine kinases provide specific tumour markers and tools for cancer diagnosis, prognosis and therapeutic applications.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Goods & Services

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.